Literature DB >> 3350821

The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine.

M Gheorghiu1, P H Lagrange, C Fillastre.   

Abstract

The level of antituberculous immunity seems to be related to the number of memory T cells induced. This may vary as a function of the multiplication and persistence of BCG in host tissues. The most important requirements for a BCG vaccine are, therefore, the immunogenicity of the strain, the high proportion of live to dead bacilli, and adequate dispersion and low levels of soluble antigens. The surface-grown Pasteur BCG vaccine contains a very high proportion of bacilli killed by ball-milling and freeze-drying. It also contains clumps and soluble antigens, all factors influencing cell-mediated immune processes and viability control. Therefore, several batches of vaccine were prepared on an industrial scale using one of the most immunogenic strains (French 1173 P2) and grown as dispersed bacilli by a modified cell type culture method. This method provided fully viable, well-dispersed vaccines which have a viability and heat stability superior to that of the classical surface-grown BCG. The immunogenicity was checked by multiplication and persistence in mouse organs and the skin reactivity and tuberculin hypersensitivity in guinea-pigs showed results comparable to those obtained with classical vaccine. Small-scale tests in children showed superior immunogenicity of the dispersed as opposed to the classical vaccine and there was no suppurative adenitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350821     DOI: 10.1016/0092-1157(88)90025-x

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  24 in total

1.  Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses.

Authors:  I Méderlé; I Bourguin; D Ensergueix; E Badell; J Moniz-Peireira; B Gicquel; N Winter
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 2.  The role of BCG vaccine in tuberculosis control.

Authors:  M Gheorghiu
Journal:  Indian J Pediatr       Date:  1990 Sep-Oct       Impact factor: 1.967

3.  Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes.

Authors:  M Abolhassani; M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.

Authors:  Dongqing Gu; Wei Chen; Youjun Mi; Xueli Gong; Tao Luo; Lang Bao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-27       Impact factor: 3.848

Review 6.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

7.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

Authors:  M R Lagranderie; A M Balazuc; E Deriaud; C D Leclerc; M Gheorghiu
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

9.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

10.  Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.

Authors:  Joan Joseph; Raquel Fernández-Lloris; Elías Pezzat; Narcís Saubi; Pere-Joan Cardona; Beatriz Mothe; Josep Maria Gatell
Journal:  J Biomed Biotechnol       Date:  2010-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.